Steglujan 15/100 mg Tablet
Ertugliflozin L-Pyroglutamic Acid 19.43mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Korea MSD Co., Ltd.
MFDS item code 201803605 · Approved 2018.09.05
This product's status changed to Approval revoked on 2025.10.13. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in patients with type 2 diabetes
This medication is used alongside dietary and exercise regimens to improve blood glucose control in patients with type 2 diabetes. It is particularly suitable for patients whose blood glucose is not adequately controlled and should be used with caution in patients with cardiovascular diseases. This medication enhances blood glucose control and aids in diabetes management.
The recommended starting dose of this medicine is ertugliflozin 5 mg/sitagliptin 100 mg once daily. This medicine is administered orally once daily in the morning, with or without food. If the 5/100 mg dose is well tolerated but additional glycemic control is needed, the dose may be increased to ertugliflozin 15 mg/sitagliptin 100 mg once daily. Patients with volume depletion should have their volume status corrected before taking this medicine [see Precautions for Use, 3. Patients Requiring Caution, 1) Volume depletion, and 4. Adverse Reactions, ○Ertugliflozin, 2) Specific adverse reactions, ① Volume depletion]. Special populations ∙ Patients with renal impairment The efficacy of this medicine depends on renal function. Assess renal function before initiating treatment and periodically during treatment [see Precautions for Use, 3. Patients Requiring Caution, 1) Volume depletion]. Initiation of this medicine is not recommended in patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2. If eGFR persistently falls below 45 mL/min/1.73 m2, this medicine should be discontinued. ∙ Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. ∙ Elderly patients Dose adjustment of ertugliflozin or sitagliptin based on age is not recommended. The risk of volume depletion should be considered. Renal function is more likely to be reduced in elderly patients. Renal function abnormalities may occur after initiating ertugliflozin, and sitagliptin is known to be primarily excreted by the kidneys. Therefore, caution should be exercised when selecting a dose for elderly patients, and periodic renal function assessments before and during treatment are recommended more frequently than for non-elderly patients. Because experience with ertugliflozin treatment in patients aged 75 years or older is limited, initiation of this medicine is not recommended [see Precautions for Use, 9. Administration to the Elderly].
This medication contains two active ingredients: citagliptin and ertugliflozin. First, this medication may cause allergic reactions, so if symptoms such as hives, skin rash, or difficulty breathing occur, discontinue use immediately and consult a physician. Second, there is a risk of acute pancreatitis, a serious inflammation of the pancreas, so if symptoms such as upper abdominal pain, vomiting, or loss of appetite arise, seek medical attention immediately. Third, this medication should not be used in patients with type 1 diabetes or those with severely impaired renal function. Patients who have had allergic reactions to this medication’s ingredients should also not take it. Fourth, patients with low blood pressure, reduced renal function, the elderly, or those taking diuretics should be monitored carefully as there is a risk of decreased blood volume and hypotension when using this medication. Fifth, patients with heart failure or at high risk of heart failure should consult a physician before taking this medication and should be monitored closely for heart failure symptoms during treatment. Sixth, this medication can cause ketoacidosis, a serious metabolic disturbance, so if symptoms such as vomiting, abdominal pain, difficulty breathing, or generalized fatigue appear, immediate medical attention is required. Seventh, this medication may cause fungal infections in the genital area, so appropriate treatment should be sought if there is genital itching or discomfort. Eighth, there is a possibility of hypoglycemia, especially if used together with other blood glucose-lowering agents like insulin or sulfonylureas, so patients should be alert for symptoms of low blood sugar. Ninth, renal function should be regularly monitored, as decreased renal function may reduce the effectiveness of this medication. Tenth, it is recommended that women who are pregnant or breastfeeding do not use this medication, and if pregnancy is confirmed, it should be discontinued immediately. Finally, this medication has not been established as safe and effective for use in children or adolescents under the age of 18, so it should not be administered to them. When taking this medication, it is essential to be aware of the above considerations and to consult medical personnel immediately if any abnormal symptoms occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering and kept at a temperature between 1 and 30 degrees Celsius. Proper storage ensures the drug's effectiveness is maintained and prevents degradation.
Brown, almond-shaped film-coated tablet with '555' embossed on one side
28 tablets
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ertugliflozin L-Pyroglutamic Acid 19.43mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Korea MSD Co., Ltd.
Ertugliflozin L-Pyroglutamic Acid 6.477mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
MSD Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.